Abstract
In the present study, the expression of bcl-2 protein in esophageal squamous cell carcinoma (SCC) and basaloid carcinoma (BC) was immunohistochemically examined, and its relation to tumor progression and postoperative survival was determined in SCC.A total of 42 SCC and 4 BC tumor samples were fixed with formalin, embedded in paraffin, and stained using monoclonal bcl-2 protein antibody, clone 124. Immunoreactivity was semiquantitatively scored, and the staining results were compared with the pathologic features and survival rates. The cytoplasm of basal cells from the normal esophageal epithelium was stained. In some well- and moderately differentiated SCCs, bcl-2 protein-positive reaction was observed in the peripheral part of the tumor cord, but in poorly differentiated SCC, the cells were weakly or hardly stained. However, in BC, the cells were strongly stained. The immunoreactivity was positive in 45.2% of the SCCs and all of the BCs. There were no significant differences in pathological features or patient survival between the bcl-2 protein-positive and protein-negative SCCs. In conclusion, the expression was not related to tumor progression and had no prognostic significance in SCC. Conversely, BC had strong immuno-histochemical expression, probably associated with the differentiation of carcinoma cells simulating the basal cells of the esophagus.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce CM (1985) The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistake in VDJ jointing. Science 229:1390–1393
Bakhshi A, Jensen JP, Goldman P, Wright JJ, McBride OW, Epstein AL, Korsmeyer SJ (1985) Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 41:899–906
Cleary ML, Sklar J (1985) Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 82:7439–7443
Cleary ML, Smith SD, Sklar J (1986) Cloning and structual analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunogloblin transcript resulting from the t(14;18) translocation. Cell 47:19–28
Seto M, Jaeger U, Hockett RD, Graninger W, Bennett S, Goldman P, Korsmeyer SJ (1988) Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J 7:123–131
Chen-Levy Z, Nourse J, Cleary ML (1989) The bcl-2 candidate proto-oncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation. Mol Cell Biol, 9:701–710
Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ (1990) Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334–336
Vaux DL, Cory S, Adams JM (1988) Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440–442
Nunez G, London L, Hockenbery D, Alexander M, Mckearn JP, Korsmeyer SJ (1990) Deregulated bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 144:3602–3610
Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ (1991) Bcl2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88:6961–6965
Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, Harris A, Gatter KC, Mason DY (1993) bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 329:690–694
Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R (1993) Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Path 143:390–400
Castle VP, Heidelberger KP, Bromberg J, Ou X, Dole M, Nunez G (1993) Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am J Pathol 143:1543–1550
Japanese Society for Esophageal Disease (1992) Guidelines for the clinical and pathologic studies on carcinoma of the esophagus, 8th edn. Kanehara, Tokyo
Hsu SM, Raine L, Fanger H (1981) A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying peptide hormones with radioimmunoassay antibodies. Am J Clin Pathol 75:734–738
Shi SR, Chaiwun B, Young L, Cote RJ, Taylor CR (1993) Antigen retrieval technique utilizing citrate buffer or urea solution for immunohistochemical demonstration of androgen receptor in folmalin-fixed paraffin sections. J Histochem Cytochem 41:1599–1640
Cattoretti G, Pileri S, Parravicini C, Becker MHG, Poggi S, Bifulco C, Key G, D'Amato L, Sabattini E, Feudale E, Reynolds F, Gerdes J, Rilke F (1993) Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J Pathol 171:83–98
Pezzella F, Tse AGD, Gordell JL, Pulford KAF, Gatter KC, Mason DY (1990) Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosornal translocation. Am J Path 137:225–232
Koide N (1994) Histochemical study on cell proliferation and cell death in esophageal carcinoma (in Japanese with English abstract). Shinshu Med J 42:378–388
Gavrieli Y, Sherman Y, Ben-Sasson SA (1992) Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493–501
Doglioni C, Dei Tos AP, Laurino L, Chiarelli C, Barbareschi M, Viale G (1994) The prevalence of bcl-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status. Virchows Arch 424:47–51
Yunis JJ, Mayer MG, Arnesen MA, Aeppli DP, Oken MM, Frizzera G (1989) bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N Eng J Med 320:1047–1054
Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, Magaud JP, Guyotat D (1993) High expression of bcl-2 protein in acute myeloid leuchemia cells in associated with poor response to chemotherapy. Blood 81:3091–3096
Piris MA, Pezela F, Martinez-Montero JC, Orradre JL, Villuendas R, Sanchez-Beato M, Cuena R, Cruz MA, Martinez B, Garrido MC, Gatter K, Aiello A, Delia D, Giardini R, Rilke F (1994) p53 and bcl-2 expression in high grade B-cell lymphomas: correlation with survival time. Br J Cancer 69:337–341
Lipponen P, Eskelinen M, Syrajanen K (1995) Expression of tumor-suppressor gene Rb, apoptosis-suppressing protein bcl-2 and c-Myc have no independent prognostic value in renal adenocarcinoma. Br J Cancer 71:863–867
Mustard RA, Ibberson O (1956) Carcinoma of the esophagus. A review of 381 cases admitted to Toronto General Hospital 1937–1953 inclusive. Ann Surg 144:927–940
Suzuki H, Nagayo T (1980) Primary tumors of the esophagus other than squamous cell carcinoma: Histologic classification and statistics in the surgical and autopsied materials in Japan. Int Adv Surg Oncol 3:73–109
Gowing NFC (1961) The pathology of the oesophagus tumours. In: Tanner NC, Smith DW (eds) Tumours of the oesophagus. Livingstone, Edinburgh, pp 91–135
McKay MJ, Bilous AM (1989) Basaloid-squamous cell carcinoma of the hypopharynx. Cancer 63:2528–2531
Takubo K, Mafune K, Tanaka Y, Miyama T, Fujita K (1991) Basaloid-squamous carcinoma of the esophagus with marked deposition of basement membrane substance. Acta Pathol Jpn 41:59–64
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Koide, N., Koike, S., Adachi, W. et al. Immunohistochemical expression of bcl-2 protein in squamous cell carcinoma and basaloid carcinoma of the esophagus. Surg Today 27, 685–691 (1997). https://doi.org/10.1007/BF02384977
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02384977